Tumor budding, a novel prognostic indicator for predicting stage progression in T1 bladder cancers

Keishiro Fukumoto, Eiji Kikuchi, Shuji Mikami, Koichiro Ogihara, Kazuhiro Matsumoto, Akira Miyajima, Mototsugu Oya

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Tumor budding has been defined as an isolated single cancer cell or a cluster composed of fewer than five cancer cells scattered in the stroma. It is a strong predictor for lymph node metastasis in T1 colorectal cancer. We introduced this concept to T1 non-muscle invasive bladder cancer and evaluated whether tumor budding could have a prognostic impact on the clinical outcome. We identified 121 consecutive patients with newly diagnosed T1 bladder cancer between 1994 and 2014 at Keio University Hospital. All slides were re-reviewed by a dedicated uropathologist. Budding foci were counted under ×200 magnification. When the number of budding foci was 10 or more, tumor budding was defined as positive. The relationship between tumor budding and clinical outcomes was assessed using a multivariate analysis. The median follow-up was 52 months. Tumor budding was positive in 21 patients (17.4%). Tumor budding was significantly associated with T1 substaging, tumor architecture and lymphovascular invasion. The 5-year progression-free survival rate in T1 bladder cancer patients with tumor budding was 53.8%, which was significantly lower than that in patients without tumor budding (88.4%, P = 0.001). A multivariate Cox regression analysis revealed that tumor budding was independently associated with stage progression (P = 0.002, hazard ratio = 4.90). In a subgroup of patients treated with bacillus Calmette-Guérin instillation (n = 88), tumor budding was also independently associated with stage progression (P = 0.003, hazard ratio = 5.65). Tumor budding may be a novel indicator for predicting stage progression in T1 bladder cancer, and would likely be easily introduced in clinical practice.

Original languageEnglish
JournalCancer Science
DOIs
Publication statusAccepted/In press - 2016

Fingerprint

Urinary Bladder Neoplasms
Neoplasms
Bacillus
Disease-Free Survival
Colorectal Neoplasms
Multivariate Analysis
Survival Rate
Lymph Nodes
Regression Analysis
Neoplasm Metastasis

Keywords

  • Disease progression
  • Pathology
  • Recurrence
  • Transitional cell
  • Urinary bladder neoplasms

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

Tumor budding, a novel prognostic indicator for predicting stage progression in T1 bladder cancers. / Fukumoto, Keishiro; Kikuchi, Eiji; Mikami, Shuji; Ogihara, Koichiro; Matsumoto, Kazuhiro; Miyajima, Akira; Oya, Mototsugu.

In: Cancer Science, 2016.

Research output: Contribution to journalArticle

@article{f1f641b495ee4e6da5c9abf114643209,
title = "Tumor budding, a novel prognostic indicator for predicting stage progression in T1 bladder cancers",
abstract = "Tumor budding has been defined as an isolated single cancer cell or a cluster composed of fewer than five cancer cells scattered in the stroma. It is a strong predictor for lymph node metastasis in T1 colorectal cancer. We introduced this concept to T1 non-muscle invasive bladder cancer and evaluated whether tumor budding could have a prognostic impact on the clinical outcome. We identified 121 consecutive patients with newly diagnosed T1 bladder cancer between 1994 and 2014 at Keio University Hospital. All slides were re-reviewed by a dedicated uropathologist. Budding foci were counted under ×200 magnification. When the number of budding foci was 10 or more, tumor budding was defined as positive. The relationship between tumor budding and clinical outcomes was assessed using a multivariate analysis. The median follow-up was 52 months. Tumor budding was positive in 21 patients (17.4{\%}). Tumor budding was significantly associated with T1 substaging, tumor architecture and lymphovascular invasion. The 5-year progression-free survival rate in T1 bladder cancer patients with tumor budding was 53.8{\%}, which was significantly lower than that in patients without tumor budding (88.4{\%}, P = 0.001). A multivariate Cox regression analysis revealed that tumor budding was independently associated with stage progression (P = 0.002, hazard ratio = 4.90). In a subgroup of patients treated with bacillus Calmette-Gu{\'e}rin instillation (n = 88), tumor budding was also independently associated with stage progression (P = 0.003, hazard ratio = 5.65). Tumor budding may be a novel indicator for predicting stage progression in T1 bladder cancer, and would likely be easily introduced in clinical practice.",
keywords = "Disease progression, Pathology, Recurrence, Transitional cell, Urinary bladder neoplasms",
author = "Keishiro Fukumoto and Eiji Kikuchi and Shuji Mikami and Koichiro Ogihara and Kazuhiro Matsumoto and Akira Miyajima and Mototsugu Oya",
year = "2016",
doi = "10.1111/cas.12990",
language = "English",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Tumor budding, a novel prognostic indicator for predicting stage progression in T1 bladder cancers

AU - Fukumoto, Keishiro

AU - Kikuchi, Eiji

AU - Mikami, Shuji

AU - Ogihara, Koichiro

AU - Matsumoto, Kazuhiro

AU - Miyajima, Akira

AU - Oya, Mototsugu

PY - 2016

Y1 - 2016

N2 - Tumor budding has been defined as an isolated single cancer cell or a cluster composed of fewer than five cancer cells scattered in the stroma. It is a strong predictor for lymph node metastasis in T1 colorectal cancer. We introduced this concept to T1 non-muscle invasive bladder cancer and evaluated whether tumor budding could have a prognostic impact on the clinical outcome. We identified 121 consecutive patients with newly diagnosed T1 bladder cancer between 1994 and 2014 at Keio University Hospital. All slides were re-reviewed by a dedicated uropathologist. Budding foci were counted under ×200 magnification. When the number of budding foci was 10 or more, tumor budding was defined as positive. The relationship between tumor budding and clinical outcomes was assessed using a multivariate analysis. The median follow-up was 52 months. Tumor budding was positive in 21 patients (17.4%). Tumor budding was significantly associated with T1 substaging, tumor architecture and lymphovascular invasion. The 5-year progression-free survival rate in T1 bladder cancer patients with tumor budding was 53.8%, which was significantly lower than that in patients without tumor budding (88.4%, P = 0.001). A multivariate Cox regression analysis revealed that tumor budding was independently associated with stage progression (P = 0.002, hazard ratio = 4.90). In a subgroup of patients treated with bacillus Calmette-Guérin instillation (n = 88), tumor budding was also independently associated with stage progression (P = 0.003, hazard ratio = 5.65). Tumor budding may be a novel indicator for predicting stage progression in T1 bladder cancer, and would likely be easily introduced in clinical practice.

AB - Tumor budding has been defined as an isolated single cancer cell or a cluster composed of fewer than five cancer cells scattered in the stroma. It is a strong predictor for lymph node metastasis in T1 colorectal cancer. We introduced this concept to T1 non-muscle invasive bladder cancer and evaluated whether tumor budding could have a prognostic impact on the clinical outcome. We identified 121 consecutive patients with newly diagnosed T1 bladder cancer between 1994 and 2014 at Keio University Hospital. All slides were re-reviewed by a dedicated uropathologist. Budding foci were counted under ×200 magnification. When the number of budding foci was 10 or more, tumor budding was defined as positive. The relationship between tumor budding and clinical outcomes was assessed using a multivariate analysis. The median follow-up was 52 months. Tumor budding was positive in 21 patients (17.4%). Tumor budding was significantly associated with T1 substaging, tumor architecture and lymphovascular invasion. The 5-year progression-free survival rate in T1 bladder cancer patients with tumor budding was 53.8%, which was significantly lower than that in patients without tumor budding (88.4%, P = 0.001). A multivariate Cox regression analysis revealed that tumor budding was independently associated with stage progression (P = 0.002, hazard ratio = 4.90). In a subgroup of patients treated with bacillus Calmette-Guérin instillation (n = 88), tumor budding was also independently associated with stage progression (P = 0.003, hazard ratio = 5.65). Tumor budding may be a novel indicator for predicting stage progression in T1 bladder cancer, and would likely be easily introduced in clinical practice.

KW - Disease progression

KW - Pathology

KW - Recurrence

KW - Transitional cell

KW - Urinary bladder neoplasms

UR - http://www.scopus.com/inward/record.url?scp=84981306474&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981306474&partnerID=8YFLogxK

U2 - 10.1111/cas.12990

DO - 10.1111/cas.12990

M3 - Article

C2 - 27317460

AN - SCOPUS:84987618959

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

ER -